Drug Approval | March 06, 2023
Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
She was the CEO of Tata Insights and Quants a Division of the Tata Industries Ltd.
The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3
This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry
Rocuronium Bromide Injection is a neuromuscular blocking agent
Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States
Jan Aushadhi highlights achievements of women of the country at 34 locations by felicitating all women stakeholders under the scheme
Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
Subscribe To Our Newsletter & Stay Updated
